US EditionPublished • loading... • Updated
Risk-Based Breast Cancer Screening Outperforms Annual Mammograms, Clinical Trial Finds
Risk-based screening tailored by genetics, lifestyle, and breast density reduced advanced cancers to 30 per 100,000 person-years, compared to 48 with standard mammograms, UCSF researchers said.
- On Dec. 12, researchers reported in JAMA that tailoring breast cancer screening to individual risk detected cancers earlier and reduced diagnoses of advanced disease.
- Risk assessment guided screening schedules using age, genetics, lifestyle, health history and breast density, with University of California-San Francisco researchers categorizing women into personalized screening categories.
- The trial enrolled more than 14,000 women , with risk categories of 26%, 8%, and 2%, and advanced cancer rates of about 30 versus 48 per 100,000 person-years.
- Researchers are now enrolling participants for a follow-up trial to better identify high-risk women, while Dr. Laura Esserman said the findings should transform guidelines and the ACR urged caution.
- The trial also offered genetic testing to all participants, flagging hereditary risks that about 30% of positives lacked a reported family history, with recruitment from September 2016–February 2023 and follow-up through September 2025 using person-years.
Insights by Ground AI
27 Articles
27 Articles
WISDOM trial weighs risk-based cancer screening
University of California, San Francisco investigators led WISDOM, a randomized comparison of risk-based breast cancer screening and annual mammography. Rates of stage ≥IIB breast cancers met a noninferiority threshold under risk-based screening, and breast biopsy rates ran higher rather than lower.
Coverage Details
Total News Sources27
Leaning Left3Leaning Right5Center6Last UpdatedBias Distribution43% Center
Bias Distribution
- 43% of the sources are Center
43% Center
L 21%
C 43%
R 36%
Factuality
To view factuality data please Upgrade to Premium
